Rallybio CorpRLYBEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Rallybio Corp is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with severe, rare diseases with high unmet medical needs. Its core development pipeline targets hematologic disorders, fetal and neonatal hemolytic disease, and complement-mediated conditions, serving patient populations primarily in North America and Europe.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Viking Global Investors LP | 11.10% | 4.2M | — | 2024-02-14 |
| Johnson & Johnson | 8.80% | 3.6M | — | 2024-07-30 |
| Nan Fung Group Holdings Limited | 6.40% | 2.4M | — | 2024-02-12 |
| FMR LLC | 5.58% | 2.3M | ▼ -1.13pp | 2024-11-12 |
| Canaan XI L.P. | 4.97% | 2.1M | — | 2024-07-30 |
| Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly | 4.70% | 1.8M | — | 2024-01-02 |
Insider Transactions
Net 90d: −$4.0K · buys $0 / sells $4.0KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-23 | Lieber Jonathan I | Chief Financial Officer | Sell (open market) | 789 | $5.06 | $4.0K |
1–1 of 1